• The cannabis industry supports communities through job creation, tax revenue generation, social equity programs, and community outreach initiatives
• ZDPY focuses on seizing direct-to-consumer real estate opportunities in the regulated cannabis market while enabling businesses to support the communities where they operate
• ZDPY’s portfolio includes properties leased to licensed cannabis operators in Arizona, Illinois, and Michigan with 100% occupancy and a weighted average lease term of 10+ years
• ZDPY anticipates more than $2.5 million from its property investment portfolio in 2024

The cannabis industry supports the community through job creation, tax revenue generation for essential services, social equity programs, philanthropic efforts, and community outreach initiatives. Additionally, it stimulates economic growth by attracting investment and revitalizing properties, ultimately contributing to community development and enhanced infrastructure.

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company, focuses on acquiring direct-to-consumer real estate opportunities in the regulated cannabis market while enabling businesses to support the communities they serve.

By investing in cannabis real estate projects and operating commercial properties leased to licensed cannabis operators, ZDPY indirectly contributes to job creation in its target areas. Further, ZDPY’s real estate development projects potentially lead to the revitalization of underutilized properties and the enhancement of local neighborhoods. By transforming properties to meet the needs of cannabis businesses, ZDPY potentially contributes to the overall improvement of community infrastructure and aesthetics.

ZDPY’s portfolio includes properties leased to licensed cannabis operators in Arizona, Illinois, and Michigan. Each project has 100% occupancy and a weighted average lease term of 10+ years, leading to estimates of more than $2.5 million in revenue for 2024.

Michigan has emerged as an example where the cannabis industry has made significant strides in community revitalization efforts. In 2023, the sector generated $87.1 million in excise tax revenue, leading to tangible improvements in public infrastructure (https://ibn.fm/9Dm8d).

Municipalities are leveraging these funds for street enhancements and park rejuvenation projects, fueled by licensing fees that reflect the industry’s growth. “This period marks an unparalleled level of street advancement in half a century,” said Mike Burns, City Manager at Lowell, Michigan. With foliage not the only thing going green, the cannabis excise tax is hailed as a key contributor to this urban metamorphosis.”

Besides contributing to local infrastructure, many states have also integrated social equity programs within their cannabis regulations to address the historical injustices of the War on Drugs. With a focus on promoting diversity and inclusion, these programs provide support and resources to individuals from communities disproportionately affected by cannabis prohibition.

Social advocates can look forward to more progress as the industry expands. According to MJBizDaily, total sales of medical and recreational cannabis in the United States reached approximately $33.6 billion by year-end 2023 (https://ibn.fm/ZjwXP). Further estimates by the research group reveal that combined retail cannabis sales in the U.S. are poised to surpass $53.5 billion by year-end 2027, leading to unprecedented opportunities for real estate companies like ZDPY.

Based in Arizona, Zoned Properties is led by Chairman and CEO Bryan McLaren, whose expertise in sustainable community and real estate development spearheads the company’s unique strategy. As the cannabis industry continues to grow, ZDPY is strongly positioned to seize real estate prospects within the swiftly expanding retail cannabis market.

For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://ibn.fm/ZDPY

• Transitioning from fossil fuel dependence to alternative, renewable energy sources has taken on increasing importance amid concerns about the growing consequences of climate change
• Federal government incentives and experimental projects are helping to drive efforts to transition the United States to greater renewable energy use from carbon-based energy sources
• Idaho-based Correlate Energy Corp. is a distributed energy solutions company making the transition to renewable energy more accessible to mid-tier companies, particularly those with nationwide portfolios that may create multiple revenue opportunities
• With proven user-friendly finance models, the company works to strategically develop, and profitably sell microgrids and localized green energy solutions, with plans to ultimately retain ownership of some of its energy systems to provide sustainable revenues

Nearly 70 percent of American adults want renewable energy sources such as wind, solar and hydrogen power to be granted developmental policy priority over fossil fuels, according to a Pew Research report last year (https://ibn.fm/ZQmJD), but renewable energy development remains a politically polarizing concern (https://ibn.fm/qShmx).

Texas, the second-largest state by geography and by population, surpassing 30 million residents in 2022 (https://ibn.fm/1rfyY), has recently reversed decades of support for renewable energy that led it to become the nation’s largest wind power producer, turning instead to fossil fuel support in a variety of government proposals (https://ibn.fm/VNrnU).

Although Texas is the largest consumer of coal power in the United States, renewable energy innovation persists in the state, highlighted perhaps by a U.S. Department of Energy experimental foray into a concentrating solar energy project that relies on using supercritical carbon dioxide to work turbines, instead of steam.

The project has the potential to eliminate concerns about the variability of wind and solar power generation, making solar power able to “pump out electricity or industrial process heat on a 24/7 basis, no matter what the sun is doing,” (https://ibn.fm/5fYYY).

Success for the government initiative could be a new shot in the arm for groups pushing the adoption of renewable energy to combat the anticipated ravages of climate change. Distributed energy solutions company Correlate Energy (OTCQB: CIPI) is a company helping to promote that adoption at a corporate level for mid-tier companies that are often overlooked by large energy companies and consulting firms in the sustainability market.

Correlate Energy’s efforts include identifying localized clean energy solutions and microgrids that the company can finance, develop, and profitably sell to its clientele. Its strategy for scale includes becoming capable of retaining ownership of some of its energy systems to provide sustainable revenues.

To date, the company has completed a number of significant solar energy projects throughout the country, such as an 8.2 MW rooftop solar energy project atop the MGM Mandalay Resort in Las Vegas, a 12.9 MW system for Arizona State University that provides 71 percent of campus solar output, a 6.48 MW project for NFL stadiums in California, New York, Washington and Massachusetts, and a 4.5 MW system for Albertsons-Safeway stores in California.

Correlate participated in a Xendee webinar last month in which company executives discussed their work with Xendee’s PROPOSE distributed energy resource platform to expedite the site analysis process and design proposals that win more deals and inspire investor confidence.

“Behind the meter solar … has been our focus for a long time, specifically on large commercial and industrial properties,” Correlate’s Solar Energy & Storage Director Jason Loyet said during the webcast (https://ibn.fm/0nzEX), showcasing a 908-kW solar project recently commissioned and successfully built in Illinois as part of the national portfolios new clients bring in. “We’re at a unique opportunity in the industry, that we really need to move through the design and really qualify the projects and the technologies around it and understand (if this is) a viable project.”

“That continuous evolution from propose to design and to operate I think is really important for customers to feel confident that they’re going to get the results that you’re presenting to them and for you internally to have confidence that you’re not going to get hung out to dry by presenting something to a client and then having to back-walk it because your real design is coming up with different answers,” Chief Product Officer Leif Elgethun said. “I think (the PROPOSE platform) runs hundreds or thousands of different scenarios to come up with the best possible way of designing the system from a sizing standpoint, but then also how are you going to dispatch it if it includes solar storage, EVs (electric vehicles) and other assets, so like literally down to the hour.”

The tool provides Correlate a powerful resource for moving the project rapidly through to completion. 

For more information, visit the company’s website at www.Correlate.Energy, including the following:

Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Fentanyl is a potent opioid that is associated with a significant risk of abuse and overdose, contributing to a major drug crisis in the United States
• Fentanyl has legitimate medical uses in managing severe and chronic pain in medical settings such as hospitals and surgical procedures
• NTRB is advancing its AVERSA(TM) technology that incorporates aversive agents to prevent abuse, diversion, misuse, and accidental exposure to opioids and other drugs with abuse potential
• NTRB was recently granted a patent for AVERSA(TM), strengthening its intellectual property portfolio in the United States and globally across 45 countries

Fentanyl, a potent opioid, poses a significant problem due to its potential for abuse with a high risk of overdose – even in small quantities. Nutriband (NASDAQ: NTRB) is advancing its AVERSA(TM) technology that features aversive agents to prevent abuse, diversion, misuse, and accidental exposure to drugs with abuse potential, specifically opioids.

“AVERSA is a platform technology that can be deployed in almost any transdermal product that carries a risk of abuse or misuse. It is our mission to reduce the risk profile of these drugs while ensuring availability for patients that need them,” said NTRB CEO Gareth Sheridan in recent statements (https://ibn.fm/C1Xiq).

The abuse of fentanyl is contributing to the worst drug crisis in the history of the United States. According to the Council on Foreign Relations, more than a million people in the United States have died of drug overdoses since 2000, and the majority of these cases were due to opioids with fentanyl being the leading cause (https://ibn.fm/y2vfV). In the last two years alone, overdose rates have been approximately 112,000 and 108,000 respectively.

Despite its potential for abuse, fentanyl has legitimate medical uses when prescribed and administered properly to treat chronic pain. Used commonly in medical settings, the drug effectively manages post-operative pain, cancer-related pain, and pain associated with severe injuries. Additionally, it is sometimes used as anesthesia during surgical procedures due to its fast-acting and short-duration properties.

NTRB is facilitating the responsible use of fentanyl through its AVERSA(TM) technology. AVERSA(TM) works by incorporating aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. By incorporating these aversive agents onto the backing of the patch, AVERSA(TM) aims to deter individuals from tampering with or abusing the medication while ensuring the medication remains accessible to patients who genuinely need it for pain management.  The Company is partnered with Kindeva Drug Delivery, utilizing Kindeva’s FDA approved Fentanyl patch and adding Nutriband’s AVERSA technology.  The Company aims to file for FDA marketing approval in 2025.

Nutriband recently announced the issuance of a new U.S. patent No. 11,759,431 for its AVERSA(TM) abuse deterrent technology by the United States Patent and Trademark Office (https://ibn.fm/tnWXi). This patent expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products.

“The issuance of this patent covering our AVERSA(TM) abuse deterrent transdermal technology that utilizes taste aversion to address a primary route of abuse of opioid patches is an important component of our global IP portfolio,” said CEO Gareth Sheridan.

“This new patent strengthens our intellectual property position, which includes patents issued in 45 countries around the world.”

Nutriband Inc. primarily engages in developing its portfolio of transdermal pharmaceutical products. Led by an experienced management team with extensive experience in the pharmaceutical sector, the company is dedicated to its mission of enhancing the safety, efficacy, and responsible use of pharmaceutical treatments for patients worldwide.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• Developments in Australia’s efforts to limit youth offender recidivism underscore the importance of being able to track select probationary participants
• Israel-based SuperCom Ltd. is positioning itself to be a world leader in providing court-administered offender tracking, which may include youths potentially prone to recidivism
• The company is growing on a global scale with contracts in Romania, Finland, Croatia, Sweden, and various states in the United States, in a marketplace with an anticipated 9.5 percent CAGR over the next five years

An Australian court’s decision to have young criminal suspects wear electronic ankle bracelet monitors is helping law enforcement advocates successfully deal with concerns about violent recidivism while court proceedings are in progress, while also allowing teen suspects to enjoy a measure of freedom while under court supervision (https://ibn.fm/gWthl).

Legal authorities affirm in the report that the technology is a sensible way of allowing suspected teen offenders to continue their normal daily activities within the parameters of court-ordered restrictions while minimizing the prospects of unlawful behaviors.

The need for such restrictions was underscored by the recent widely publicized “terrorist” stabbing attack on congregants at a Sydney church, in which a teen suspect was identified as a recently arrested knife crime offender who was freed on a good behavior bond (https://ibn.fm/6cWYI).

Electronic-monitoring (“EM”) security solutions developer SuperCom (NASDAQ: SPCB) is building clientele among government agencies worldwide to improve public safety while also limiting the stigma that teen advocates worry about in regard to wearing the monitoring bracelets.

SuperCom’s PureSecurity Suite combines its EM technology platform with EM-related services administered by SuperCom subsidiary Leaders in Community Alternatives (“LCA”) to provide an efficient and reliable, but discrete, set of cutting-edge tools for tracking offenders.

The company is rolling out its services on a global scale, with the majority of its projects widely spread across Europe and the United States.

SuperCom’s monitors are easily concealable to reduce concerns about unnecessary stigmatizing of youthful wearers, a concern in the community. The product suite’s artificial intelligence (“AI”) adoption delivers powerful ability for optimal decision-making through effective data analysis, predictive modeling, and streamlined operation.

Its ultra-lightweight base station, long battery life and onboard GPS tracking with field-proven RFID, are appealing for mobile operation. 

Market potential for the court-administered electronic monitoring sector is expected to reach $2.3 billion by 2029 at a 9.5 percent CAGR (https://ibn.fm/rvZPx), highlighting the value of SuperCom’s efforts to position itself at the front of its sector.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• EAWD is a green-tech engineering solutions company that builds water and energy systems for clients, including private companies, government entities and NGOs
• The company has sold and deployed its water systems in Mexico and Germany
• Using its patent-pending design, EAWD is working to build and operate off-grid EV charging stations in Germany
• In December 2023, the company announced a joint Memorandum of Understanding to build the first off-grid atmosphere water generation plant in North America

Energy and Water Development (OTCQB: EAWD) is a green-tech engineering solutions company focused on delivering water and energy to extreme environments. The company builds water and energy systems out of already existing, proven technologies, utilizing its patent-pending systems configuration and technical know-how to customize solutions to meet clients’ needs. To date, two water systems have been sold and deployed in Mexico and Germany, and the company is working to fulfill additional orders.

Using its patent-pending design, EAWD is working to build and operate off-grid EV charging stations in Germany. The company is a United Nations-accredited vendor and offers design, construction, maintenance and specialty consulting services to private companies, government entities and non-government organizations for the sustainable supply of energy and water.

EAWD focuses on three main aspects of the water and energy business: (1) generation, (2) supply and (3) maintenance. The green tech industry is constantly evolving due to ongoing and increasing water scarcity, as well as increased energy needs in the world. Therefore, the company believes that by designing sustainable and renewable solutions to these problems, EAWD will become an essential component of a rapidly growing industry with many new markets.

EAWD’s approach seeks to assist businesses with the growth and development of their general operations by ensuring the efficient, profitable and sustainable supply and generation of water and energy, allowing its potential customers to focus on their business while adopting strategies of sustainability.

By using the state-of-the-art technological solutions and technologies identified, designed and provided by EAWD and its collaborators, the company believes that its potential clients will be free to focus on the performance of their operations, as well as with the water and energy consumption or generation regulations within their industries.

EAWD is headquartered in Saint Petersburg, Florida, with operations in Germany and Mexico.

Products

In view of the increased worldwide demand for water and energy, EAWD’s business goals are focused on self-sufficient energy-supplied water generation and green energy production. To accomplish this, the company set out to establish an outsourcing green tech platform to commercialize its state-of-the-art technologies while providing engineering and technical consultation services to design the most sustainable technological solutions that can provide water and energy.

The company has sought potential collaboration with green tech research and development centers in Europe and has established its operating subsidiaries in Hamburg, Germany, where EAWD has started to assemble its patent-pending innovative off-grid, self-sufficient energy supply atmosphere water generation (“AWG”) systems.

EAWD Deutschland and EAWD Logistik operate in Hamburg, Germany, to meet the increasing demands of water and energy generation projects around the world, as well as to operate the solar-powered EAWD Off-Grid EV Charging Stations, EAWD’s newest product.

The company expects to offer sustainable added value to each project it takes on, while generating revenue from the sale of EAWD Off-Grid AWG Systems, EAWD Off-Grid EV Charging Stations, EAWD Off-Grid Power Systems and EAWD Off-Grid Water Purification Systems; royalties from the commercialization of energy and water in certain cases; and licensing of its innovated technologies, along with its engineering, technical consulting and project management services.

EAWD continues to be a development stage company. It presently assembles its EAWD Off-Grid AWG Systems and EAWD Off-Grid EV Charging Stations at its workshop in Germany and outsources most of its engineering and technical services, as well as services relating to the promotion, sale and distribution of its products.

Market Opportunity

According to a report by Allied Market Research, a global market research, consulting and advisory firm, the worldwide green technology and sustainability market was valued at $10.32 billion in 2020 and is projected to reach a value of $74.64 billion by 2030, growing at a CAGR of 21.9% during the forecast period.

A surge in environmental awareness and increasing concerns among organizations and individuals about climate change drive the growth of the market. Furthermore, an increase in consumer and industrial interest for the use of clean energy resources are among some of the major factors expected to boost growth of the market in the coming years, according to the report.

The expected rise in favorable government and private initiatives to tackle climate change and air pollution represent an opportunistic factor of the market. An increase in energy consumption and rise in greenhouse gas emissions are major factors that drive the development of green technology innovations, the report states.

Management Team

Irma Velazquez is CEO and Vice Chair at EAWD. She brings certified expertise in sustainable development and large-scale project management to the company. She formerly worked for United Nations agencies including the World Health Organization, Farmaciens Sans Frontieres, Red Cross and Crescent Societies, where she served in the positions of Information Technology Manager, Sustainable Development Manager, Programme Manager and Disaster and Crisis Management Coordinator. She has a master’s in sciences from the Erasmus University of Rotterdam. She speaks French, English and Spanish.

Ralph Hofmeier is Chief Technology Officer and Chairman at EAWD. He brings a mechanical engineering background to the company and previously served as President of Powermax Energy & Business Solutions Inc. When that company merged with EAWD, he served as President and CEO of Directors of EAWD. Over the last 20 years, he has established and developed several multinational companies in green tech distribution and commercialization. He speaks German and English.

For more information, visit the company’s website at www.Energy-Water.com.

NOTE TO INVESTORS: The latest news and updates relating to EAWD are available in the company’s newsroom at http://ibn.fm/EAWD

• CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization
• Treatment with CNM-Au8 investigated in clinical trials adjunctive to standard-of-care exhibits no known drug interactions, and aims to enhance function and survival
• Nearly 90,000 people are diagnosed with Parkinson’s disease every year with no approved drug to slow or halt disease progression currently available
• The Parkinson’s disease treatment market was valued at $4.61 billion in 2022 and is expected to reach $11.98 billion by 2030

In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including Parkinson’s disease (“PD”), amyotrophic lateral sclerosis (“ALS”), and multiple sclerosis (“MS”). Clene is developing its lead drug candidate CNM-Au8(R) for potential treatment of these neurodegenerative diseases. CNM-Au8 is an oral suspension designed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy-producing reactions that enable neuroprotection and remyelination. The result is an increase in neuronal and glial resilience to disease-relevant stressors.

In March 2021, Clene was awarded a grant from The Michael J Fox Foundation for Parkinson’s Research (“MJFF”) to accelerate the development of CNM-Au8 as a treatment for PD. The funding supports efficacy studies in a human cell culture model of PD that utilizes skin cells from individuals with PD. The cells are then converted in the laboratory to dopaminergic neurons that exhibit many aspects of the disease state. The research, led by Karen Ho, PhD, VP Translational Medicine at Clene, was a collaboration with Dr. Jerome Mertens while he was Assistant Professor at the University of Innsbruck (currently Associate Professor in the Department of Neurosciences of the University of California, San Diego) and is currently a collaboration with Dr. Fred (“Rusty”) Gage, Vi and John Adler Chair for Research on Age-Related Neurodegenerative Disease, Professor of Genetics of the Salk Institute. These two scientists are world-renowned researchers who pioneered the specific techniques to generate the human cell model utilized for the project. The team is exploring multiple aspects of the effects of CNM-Au8 on PD neurons, including potential improvements in mitochondrial function and effects on transcriptomic profiles in comparison to untreated healthy and disease controls. Results from the study are expected in Q2 2024.

The peer-reviewed publication, “Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials,” was published in Journal of Nanobiotechnology in December 2023 (https://link.springer.com/article/10.1186/s12951-023-02236-z). The study demonstrated that oral daily doses of CNM-Au8 over 12 weeks leads to increased levels of brain metabolites associated with improved mitochondrial function and brain health in these diseases.

Over 600 cumulative years of CNM-Au8 patient exposure across ALS, MS, and PD trials and compassionate use programs have shown no safety concerns. With safety, early efficacy, and brain target engagement data in hand for PD, Clene is advancing CNM-Au8’s development as a potential first-in-class treatment for PD.

A Parkinson’s Foundation-backed study in 2022 found that nearly 90,000 people are diagnosed with Parkinson’s disease every year – which is approximately the amount of fans at the Rose Bowl Stadium. This number represents a 50% increase from the previous estimated rate of 60,000 diagnoses annually.

“These updated estimates of incidence are necessary for understanding disease risk, planning health care delivery, and addressing care disparities,” said James Beck, Ph.D., Parkinson’s Foundation Chief Scientific Officer (https://ibn.fm/0xzdX). “Knowing this information will allow us to better serve people with Parkinson’s and their families and plan for adequate health care services in the future.”

The Parkinson’s disease treatment market was valued at $4.61 billion in 2022. It is expected to grow at a CAGR of 12.1%, resulting in an estimated value of $11.98 billion by 2030. The market’s growth is supported by the increasing geriatric population, the high burden of Parkinson’s disease in Western countries, and the strong product pipeline of disease-modifying therapies. It is estimated that Parkinson’s disease affects around 1% of the total population aged 60 years and older and rises to 5% for 85 years and older (https://ibn.fm/3ySss).

CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• D-Wave’s Qubits 2024 annual quantum computing conference will take place in Boston, Massachusetts, on June 17 and 18, 2024
• The two-day event will explore the transformative potential of D-Wave’s quantum technologies as they tackle complex computational challenges across supply chain logistics, manufacturing, government, and the life sciences sectors
• Participants will learn about D-Wave customers’ powerful quantum-hybrid applications, the company’s latest quantum technology innovations, and updates on the company’s latest groundbreaking scientific research

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, recently announced that its Qubits 2024 quantum computing conference will take place in Boston, Massachusetts, on June 17 and 18, 2024. The conference theme will be “Success, Powered by Quantum.” It will demonstrate how D-Wave, partners, and customers such as Momentum Worldwide (part of Interpublic Group), Los Alamos National Lab, Zapata AI, and others are achieving measurable outcomes with D-Wave’s innovative annealing quantum computing technology (https://ibn.fm/cmO6R).

This two-day event will delve into the transformative potential of D-Wave’s quantum technologies as they tackle complex computational challenges across supply chain logistics, manufacturing, government, and the life sciences sectors. The agenda will feature live demonstrations of quantum advancements, product updates, an overview of the company’s most recent scientific achievements, and insights into customer projects, spanning ongoing developments and active deployments.

“We are thrilled to bring Qubits to the global innovation hub of Boston this year, where we will share the incredible momentum we are seeing as our quantum technologies cross the chasm from experimentation to operational use,” said Dr. Alan Baratz, CEO of D-Wave. “This is the must-attend event of the year for anyone looking to understand how today’s quantum technology is transforming business, especially as it merges with AI to fuel the next generation of groundbreaking applications.”

D-Wave will offer a free live stream of the first day’s morning talks, allowing participants worldwide to virtually attend. To register for Qubits, visit www.qubits.com.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in the company’s other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

• SUIC and Beneway USA have rolled out a proprietary B2B2C system, a superior all-in-one payment and total financing solution that combines the capabilities and benefits of SUIC’s B2B e-commerce model with those of its proprietary B2C platform
• The B2B model streamlines business processes and enables businesses to develop and implement substantial growth opportunities as well as optimize costs
• The all-in-one B2C platform integrates payment systems, electronic invoice devices, mobile cash registers, POS system devices, enterprise resource planning, big data, AI, value-added cloud services, and other services
• SUIC hopes the B2B2C system, combined with cutting-edge technologies and solutions the company continues to adopt, will sustain rapid growth
• The company is confident that the B2B2C system will not only boost the IPO activity of Beneway USA but also retain its strong momentum into Q2 2024

SUIC Worldwide Holdings (OTC: SUIC), SUIC is the largest shareholder and major operating partner of Beneway Holdings Group, Ltd. USA (“Beneway USA”), recently announced a positive development expected to boost the IPO activity of Beneway USA. The announcement focused on the capabilities of SUIC and Beneway USA’s proprietary B2B2C system (https://ibn.fm/2WJFP).

The B2B2C system is a superior all-in-one payment and total financing solution that combines the capabilities and benefits of SUIC’s B2B e-commerce model with those of its proprietary B2C platform. For its part, the B2B model enables businesses to develop and implement substantial growth opportunities as well as optimize costs. It streamlines business processes such as purchase order payments and inventory control and offers financing services, an AI credit system, and big data.

On the other hand, the B2C platform is an all-in-one product designed for merchants. Developed and offered by Boom FinTech Inc., a major fintech subsidiary of Beneway USA, the platform integrates payment systems, electronic invoice devices, mobile cash registers, POS system devices, enterprise resource planning, big data, AI, value-added cloud services, and other services. It allows merchants to use either the fully integrated system or just the functions and features they need. The platform is supported by nine fintech patents.

By combining the B2B model and the B2C platform, the company’s B2B2C system is the best of both worlds. It provides a platform that facilitates financing and other business operations, thus offering strategic planning functions that blend business financing and fintech solutions with inventory management systems. This, the company says, complements and bolsters sales and marketing channels of businesses’ partner merchants, franchisees, and suppliers around the world.

The B2B2C system is a result of various milestones SUIC and Beneway USA have progressively completed. For instance, SUIC and Boom Fintech recently entered into an agreement with BD Bankers to access credit of up to $100 million in Intellectual Property (“IP”) financing intended for the integration of advanced systems and patents held by Boom Fintech. According to the company, the IP financing will be used in the B2B financing of its merchants as well as to support their development of B2B technology. SUIC hopes the financing will bolster supply chain integration for suppliers (https://ibn.fm/nU64m).

Still, SUIC continues to adopt cutting-edge technologies and solutions to integrate its e-commerce operations within the global supply chain financing market. The company expects these technologies and solutions will sustain rapid growth driven by seamless digital payment methods and boost competition with brick-and-mortar establishments. In fact, the company intends to move into the major markets of the U.S., Europe, and other parts of the world as it builds a cohesive network, SUIC CEO Hank Wang said.

“Our comprehensive financial products and services are designed to advance our business strategies and solidify our equity value and future returns, especially for our shareholders. We expect that the borrowing and lending market will inflate up to 10 times the current supply chain financing market,” conveyed Mr. Wang, CEO of SUIC.

SUIC is confident that the B2B2C system will not only boost the IPO activity of Beneway USA but also retain its strong momentum into Q2 2024. It will also enable the company to tap into the growing global supply chain financial market, which is expected to reach $13.4 billion by 2025 from $6 billion in 2021, an 8.8% CAGR (https://ibn.fm/SUSrx). And with 60% of this market comprising small and medium-sized retailers, which constitute SUIC’s target market, according to the news release, the company is eying a significant share of the multi-trillion-dollar market.

For more information, visit the company’s website at www.SinoUnitedCo.com.

NOTE TO INVESTORS: The latest news and updates relating to SUIC are available in the company’s newsroom at https://ibn.fm/SUIC

• Lexaria, a global innovator in drug delivery platforms, has received approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board
• GLP-1 drugs are utilized in the treatment of type 2 diabetes and obesity, a huge market, and are typically administered by painful and expensive injection, offering a major opportunity for Lexaria’s oral delivery platform
• This approval sets the company up for dosing within 30 days or less, with tentative study completion dates for this summer
• The study will comprise two study arms, the second study arm will investigate whether Lexaria’s patented DehydraTECH(TM)-enhanced semaglutide can effectively absorb into the sublingual/buccal tissues of the mouth with fewer side effects
• For Lexaria, this milestone brings it closer to its objective of forging strategic partnerships with leading industry players, ultimately growing shareholder value

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board. The potential use of Lexaria’s oral delivery platform for GLP-1 drugs, typically administered by injection or stomach-upsetting tablets, represents a massive market opportunity. This study approval marks a milestone for the company, with the first dosing set to begin within 30 days or less, and with tentative completion dates for this summer (https://ibn.fm/XSHbz).

The human pilot study will seek to explore Lexaria’s patented DehydraTECH(TM) technology and its overall effectiveness in the delivery of glucagon-like peptide-1 (“GLP-1”). It will involve up to 9 healthy volunteers and feature two study arms, each evaluating tolerability, blood absorption levels, and blood sugar control.

The first study arm will use a Rybelsus(R) composition processed with DehydraTECH and delivered within swallowed capsules. The second arm will explore an oral dissolvable tablet formulation with DehydraTECH-powered semaglutide from Rybelsus(R). This will mark the very first study design to investigate whether DehydraTECH-enhanced semaglutide can effectively absorb into the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed administration and with some adequate level of blood absorption.

Earlier in March, Lexaria announced having hired a contract research organization (“CRO”) to perform this specific study, described as a randomized, crossover, placebo-controlled investigation (https://ibn.fm/Qgmg3). This ethics review board approval is a testament to the steady progress of the company. It also allows Lexaria to maintain its current momentum by meeting the study objectives and realizing the timelines set out at the beginning of the year. More importantly, these milestones inch the company closer to forging strategic partnerships with leading industry players, which would be integral in growing shareholder value.

“I am excited about this Study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” noted Chris Bunka, Lexaria’s CEO.

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” he added.

Previous studies have demonstrated DehydraTECH’s ability to improve the delivery of certain drugs destined for the bloodstream. Lexaria hopes to replicate these results in this study to usher in a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets. Its management is optimistic about the study results, and the ethics review board approval brings the company closer to realizing this objective.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

The SPAC Conference 2024 Hosted by DealFlow Events

Successful people know when facing a business challenge their best weapon is information.

Anyone involved in any way with special purpose acquisition companies cannot afford to miss The SPAC Conference 2024 coming up fast. This best-in-class event set for June 11-12 delivers the vital information and insight you need to overcome challenges and take full advantage of the capital-raise benefits available through the SPAC market.

DealFlow’s annual SPAC Conference will be held at the luxurious Westchester Country Club in Rye, New York, a superb venue for networking and learning. This annual event is widely known as the most important forum for SPAC knowledge and making new connections. This conference is where the industry’s thought-leaders gather to discuss near-term strategies for deal-making and the longer-term prognosis of the market. Be assured that the event is expected to reach capacity, so reserve your seat now while there’s still time.

Are you the executive of a private company thinking about going public via a SPAC merger? You may be eligible for a free ticket to the conference. Learn more.

SPACs continue to provide a quick and streamlined process to go public, giving investors greater flexibility in deal structures. However, navigating the world of SPACs is becoming increasingly complex and requires a comprehensive understanding of financial, regulatory and strategic issues.

Investors require a solid grasp of financial analysis and valuation techniques for evaluating SPAC investments and identifying potential opportunities. Understanding the intricacies of SPAC structures, including dilution, redemption rights, and sponsor incentives, is crucial for making informed investment decisions.

The future of SPACs remains bright, however, maximizing their potential requires a solid understanding of these emerging issues. The SPAC Conference 2024 is designed to give market participants an edge in navigating the world of SPACs in today’s investment environment and beyond.

In plain terms, those who attend this conference will come away with a competitive edge over those who do not.

It’s worth your time. We’ve assembled the most experienced and respected professionals working in SPACs today. Their panels and presentations during this two-day event give context to the current state of the market, while exploring what’s to come.

Learn the traits of successful SPAC sponsors. Hear from accounting experts on reporting the numbers throughout the blank-check process. Get the details of recent SPAC litigation, including case examples – so you can avoid the mistakes others have made. Discover how deals are getting done in today’s market.

This represents just a fraction of the expert programming you will experience during the two-day conference. Explore the full agenda.

An intense event of learning and networking deserves an equal amount of fun both during the sessions and at day’s end. DealFlow Events delivers on this score, too. We’re gathering at the luxurious Westchester Country Club, where a variety of entertainment awaits.

This event is more than just a conference. This is your chance to unwind, refresh, learn from and meet with a deep bench of experts, and network with other professionals who understand the transformative power of SPACs to help private companies succeed in the public markets.

Register now while there’s still time. We look forward to seeing you soon at The Westchester Country Club.